Prurigo Nodularis market to exhibit growth at a CAGR of 23.2% (2020-2034), driven by strong uptake of DUPIXENT, recent approval of NEMLUVIO, promising JAK and OX40 inhibitors in the Pipeline, along with rising prevalence | DelveInsight

The prurigo nodularis treatment landscape has been evolving in recent years, with increasing attention from the pharmaceutical industry due to the chronic and debilitating nature of the condition. There is growing recognition of the need for effective treatments that can break the…